Companies / Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals, Inc.

Nasdaq: ADILCIK 1513525CHARLOTTESVILLE, VA

Financials

Revenue—
Net income$-7.98M
Total debt—
Cash$5.88M
Diluted EPS$-11.93
Shares outstanding2.1M

Ownership

2.1M shares outstanding · as of May 6, 2026
1.9%Insiders
Ownership
Insiders1.89%40,417
10%+ / strategic130.60%2,799,643
Institutions1.24%26,480
Public float0.00%0

Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 1

View all →
Insider% of sharesShares
Claiborne Cary JCEOChief Executive Officer · Director
1.89%40,417

Institutional holders 4

View all →
HolderValue% of shares
Geode Capital Management, LLC$43.4K1.13%
Manchester Capital Management LLC$3.4K0.09%
BlackRock, Inc.$7780.01%
Northwestern Mutual Wealth Management Co$7<0.01%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Apr 7, 2026Claiborne Cary J
CEO
GrantCommon Stock$0+38K
+1561.88%
40,417
1.89% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Armistice Capital, LLCPassive13G—2,799,643—

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
ADILCommon StockEquity00688A304BBG00HNGDTR4